On Wednesday, Citi maintained a Buy rating on Stryker (NYSE: SYK) and increased the price target to $411 from $406. This adjustment follows Stryker's third-quarter earnings for 2024, which exceeded market expectations.
The company reported revenues of $5.49 billion, a 12.0% increase excluding foreign exchange (FX) impacts, and an 11.5% rise on an organic basis, surpassing the consensus estimate of $5.37 billion. The Orthopaedics/Spine and MedSurg divisions contributed significantly to this performance, with revenues of $2.270 billion and $3.224 billion, respectively, both exceeding consensus projections.
Stryker's product categories showed remarkable growth, with six out of ten achieving double-digit increases. Notably, Knees and Hips sales grew by 10.7% and 16.2%, respectively, with organic growth for Hips around 10%. The Endoscopy and Medical segments also saw substantial revenue increases of 12.5% and 17.7%, respectively. These figures indicate a robust demand for Stryker's offerings in the medical technology market.
The company not only delivered strong revenue but also saw an expansion in its operating margins, which rose to 24.7% from 23.4% year-over-year. This improvement in profitability contributed to an earnings per share (EPS) of $2.87, a 16.7% increase from the previous year, which outperformed the consensus estimate of $2.77.
In response to the better-than-expected results, Stryker's management has revised its full-year revenue guidance upward to a range of 9.5%-10.0%, factoring in favorable pricing of 0.5%-1.0%. The EPS guidance was also adjusted to a range of $12.00 to $12.10, up from the previous forecast of $11.90 to $12.10, despite a $0.10 impact from unfavorable FX movements. This new guidance is set against a consensus EPS estimate of $12.01.
Citi's revised price target reflects confidence in Stryker's continued performance, underpinned by strong quarterly results and positive management outlook. The company's ability to deliver double-digit revenue and EPS growth alongside operating margin expansion has reinforced the firm's Buy rating on Stryker's shares.
In other recent news, Stryker Corporation (NYSE:SYK)'s third-quarter earnings and revenue surpassed analyst expectations, leading to an upward revision of their full-year guidance. The medical technology company reported adjusted earnings per share of $2.87, exceeding the analyst consensus by $0.10. The quarter's revenue was $5.49 billion, surpassing estimates of $5.37 billion, marking an 11.9% year-over-year increase.
This growth was primarily driven by a 11.5% rise in organic net sales, with the MedSurg and Neurotechnology segment leading the growth with a 12.8% increase in net sales to $3.2 billion.
Canaccord Genuity maintained a Buy rating on Stryker and increased the price target to $400 from $360, recognizing Stryker's significant third-quarter performance. Similarly, BTIG maintained a Buy rating on Stryker and raised its shares target to $394 from $383 in response to the company's third-quarter results.
Stryker's strategy continues to prioritize mergers and acquisitions as a primary method for cash allocation. The company also highlighted a record number of global installations of its Mako robotic-arm assisted surgery system in the third quarter. Looking ahead, Stryker anticipates the full launch of its Pangea plating system in the United States in the second half of 2025.
InvestingPro Insights
Stryker's strong financial performance, as highlighted in the article, is further supported by data from InvestingPro. The company's revenue growth of 9.94% over the last twelve months aligns with management's revised full-year guidance of 9.5%-10.0%. Additionally, Stryker's operating income margin of 20.71% reflects the company's ability to maintain profitability while expanding its market presence.
InvestingPro Tips indicate that Stryker has raised its dividend for 14 consecutive years, demonstrating a commitment to shareholder returns that complements its growth strategy. The company's dividend yield stands at 0.89%, with a dividend growth rate of 6.67% over the last twelve months. This consistent dividend policy may be attractive to investors seeking both growth and income.
The stock's performance has been robust, with a one-year price total return of 38.03%, significantly outpacing the broader market. This aligns with Citi's bullish outlook and increased price target. However, investors should note that Stryker is trading at a high P/E ratio of 39.8, which may indicate that much of its near-term growth potential is already priced in.
For those interested in a deeper analysis, InvestingPro offers 11 additional tips that could provide further insights into Stryker's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.